High flow nasal cannula versus noninvasive ventilation in the treatment of acute hypercapnic respiratory failure: A systematic review and meta‐analysis
The Clinical Respiratory Journal · 2023-11 · 17 (11) · 1091-1102
DOI: 10.1111/crj.13695 ↗Kurz gefasst
Metaanalyse in der Zeitschrift The Clinical Respiratory Journal, online erschienen am 12.09.2023. Verfasst von Aisling C Fahey und 3 weiteren Autor:innen. Beteiligte Einrichtung: Catherine McAuley School of Nursing and Midwifery, University College Cork, Cork, Ireland. Hauptthemen laut MEDLINE: Noninvasive Ventilation, Respiratory Insufficiency, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chronic obstructive pulmonary disease can lead to acute hypercapnic respiratory failure (AHRF), often treated using noninvasive ventilation (NIV). Emerging research suggests the potential utility of high flow nasal cannula (HFNC) for AHRF. This systematic review and meta‐analysis aimed to determine the effect of HFNC versus NIV on AHRF management. A search of electronic databases (CINAHL, MEDLINE, and Academic Search Complete), web sources, and trial registries was last conducted on 9 February 2023. Quality and risk of bias assessments were conducted. Meta‐analyses were used to synthesise data. Seven randomised controlled trials were included. No statistically significant differences between HFNC and NIV were found within the following outcomes of interest: (i) correction of pCO2: standardised mean difference (SMD) = −0.16, 95% confidence interval (CI) (−0.34 to 0.02), p = 0.08; (ii) correction of pH: SMD = −0.05, 95% CI (−0.25 to 0.14), p = 0.59; (iii) correction of pO2: SMD = −0.15, 95% CI (−0.40 to 0.09), p = 0.22; (iv) intubation rates: risk ratio (RR) = 0.87, 95% CI (0.41 to 1.82), p = 0.71; (v) mortality rates: RR = 0.85, 95% CI (0.47 to 1.56), p = 0.61; and (vi) treatment switch: RR = 1.30, 95% CI (0.43 to 3.94), p = 0.64. More controlled trials with large sample sizes are required to investigate the management of AHRF of various aetiologies. HFNC may be used as a final exhaustive measure for COPD‐related AHRF where NIV is not tolerated, and when it is not clinically indicated to extend to endotracheal intubation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Catherine McAuley School of Nursing and Midwifery, University College Cork, Cork, Ireland.
- Kerry Mental Health Services, Cork/Kerry Community Healthcare, Health Service Executive, Tralee, Co. Kerry, Ireland.
- Health Service Executive National eRostering Project, Community Healthcare Operations Improvement and Change, St. Loman's Hospital, Lucan, Co. Dublin, Ireland.
ORCID-Profile: Mohamad M Saab
Zitieren
APA
Fahey, A. C., O'Connell, M., Cornally, N., & Saab, M. M. (2023). High flow nasal cannula versus noninvasive ventilation in the treatment of acute hypercapnic respiratory failure: A systematic review and meta‐analysis. The Clinical Respiratory Journal, 17(11), 1091-1102. https://doi.org/10.1111/crj.13695
Vancouver
Fahey AC, O'Connell M, Cornally N, Saab MM. High flow nasal cannula versus noninvasive ventilation in the treatment of acute hypercapnic respiratory failure: A systematic review and meta‐analysis. The Clinical Respiratory Journal. 2023;17(11):1091-1102. doi:10.1111/crj.13695
BibTeX
@article{Fahey2023,
author = {Fahey, Aisling C and O'Connell, Martina and Cornally, Nicola and Saab, Mohamad M},
title = {High flow nasal cannula versus noninvasive ventilation in the treatment of acute hypercapnic respiratory failure: A systematic review and meta‐analysis},
journal = {The Clinical Respiratory Journal},
year = {2023},
volume = {17},
number = {11},
pages = {1091--1102},
doi = {10.1111/crj.13695}
}
EUVIMED